Terms: = Lymphoma AND DUX4L1, DUX4, P0CJ90, P0CJ89, P0CJ88, P0CJ86, P0CJ85, 22947 AND Treatment
24 results:
1. CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
Buldini B; Varotto E; Maurer-Granofszky M; Gaipa G; Schumich A; Brüggemann M; Mejstrikova E; Cazzaniga G; Hrusak O; Szczepanowski M; Scarparo P; Zimmermann M; Strehl S; Schinnerl D; Zaliova M; Karawajew L; Bourquin JP; Feuerstein T; Cario G; Alten J; Möricke A; Biffi A; Parasole R; Fagioli F; Valsecchi MG; Biondi A; Locatelli F; Attarbaschi A; Schrappe M; Conter V; Basso G; Dworzak MN
Blood; 2024 Apr; 143(17):1738-1751. PubMed ID: 38215390
[TBL] [Abstract] [Full Text] [Related]
2. Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia.
Shakah H; Tbakhi A; Khudirat S; Abweh RA; Hasasna N; Alwhaidi A; Khoujah A; Barakat F
J Int Med Res; 2023 Oct; 51(10):3000605231203842. PubMed ID: 37818740
[TBL] [Abstract] [Full Text] [Related]
3. Transcription factor abnormalities in B-ALL leukemogenesis and treatment.
Yin H; Wang J; Tan Y; Jiang M; Zhang H; Meng G
Trends Cancer; 2023 Oct; 9(10):855-870. PubMed ID: 37407363
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia.
Leongamornlert D; Gutiérrez-Abril J; Lee S; Barretta E; Creasey T; Gundem G; Levine MF; Arango-Ossa JE; Liosis K; Medina-Martinez JS; Zuborne Alapi K; Kirkwood AA; Clifton-Hadley L; Patrick P; Jones D; O'Neill L; Butler AP; Harrison CJ; Campbell P; Patel B; Moorman AV; Fielding AK; Papaemmanuil E
Blood Adv; 2023 Aug; 7(15):3862-3873. PubMed ID: 36867579
[TBL] [Abstract] [Full Text] [Related]
5. Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia.
Ryan SL; Peden JF; Kingsbury Z; Schwab CJ; James T; Polonen P; Mijuskovic M; Becq J; Yim R; Cranston RE; Hedges DJ; Roberts KG; Mullighan CG; Vora A; Russell LJ; Bain R; Moorman AV; Bentley DR; Harrison CJ; Ross MT
Leukemia; 2023 Mar; 37(3):518-528. PubMed ID: 36658389
[TBL] [Abstract] [Full Text] [Related]
6. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.
Schwab C; Cranston RE; Ryan SL; Butler E; Winterman E; Hawking Z; Bashton M; Enshaei A; Russell LJ; Kingsbury Z; Peden JF; Barretta E; Murray J; Gibson J; Hinchliffe AC; Bain R; Vora A; Bentley DR; Ross MT; Moorman AV; Harrison CJ
Leukemia; 2023 Mar; 37(3):529-538. PubMed ID: 36550215
[TBL] [Abstract] [Full Text] [Related]
7. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract] [Full Text] [Related]
8. RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).
Rehn J; Mayoh C; Heatley SL; McClure BJ; Eadie LN; Schutz C; Yeung DT; Cowley MJ; Breen J; White DL
PLoS Genet; 2022 Oct; 18(10):e1010300. PubMed ID: 36251721
[TBL] [Abstract] [Full Text] [Related]
9. Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.
Lee SHR; Antillon-Klussmann F; Pei D; Yang W; Roberts KG; Li Z; Devidas M; Yang W; Najera C; Lin HP; Tan AM; Ariffin H; Cheng C; Evans WE; Hunger SP; Jeha S; Mullighan CG; Loh ML; Yeoh AEJ; Pui CH; Yang JJ
JAMA Oncol; 2022 Mar; 8(3):354-363. PubMed ID: 35084434
[TBL] [Abstract] [Full Text] [Related]
10. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
Schwab CJ; Murdy D; Butler E; Enshaei A; Winterman E; Cranston RE; Ryan S; Barretta E; Hawking Z; Murray J; Antony G; Vora A; Moorman AV; Harrison CJ
Br J Haematol; 2022 Feb; 196(3):753-763. PubMed ID: 34676543
[TBL] [Abstract] [Full Text] [Related]
11. In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
Carlet M; Völse K; Vergalli J; Becker M; Herold T; Arner A; Senft D; Jurinovic V; Liu WH; Gao Y; Dill V; Fehse B; Baldus CD; Bastian L; Lenk L; Schewe DM; Bagnoli JW; Vick B; Schmid JP; Wilhelm A; Marschalek R; Jost PJ; Miething C; Riecken K; Schmidt-Supprian M; Binder V; Jeremias I
Nat Commun; 2021 Sep; 12(1):5655. PubMed ID: 34580292
[TBL] [Abstract] [Full Text] [Related]
12. Distinct clinical characteristics of dux4- and PAX5-altered childhood B-lymphoblastic leukemia.
Li Z; Lee SHR; Chin WHN; Lu Y; Jiang N; Lim EH; Coustan-Smith E; Chiew KH; Oh BLZ; Koh GS; Chen Z; Kham SKY; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
Blood Adv; 2021 Dec; 5(23):5226-5238. PubMed ID: 34547766
[TBL] [Abstract] [Full Text] [Related]
13. Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.
Li J; Dai Y; Wu L; Zhang M; Ouyang W; Huang J; Chen S
Front Med; 2021 Jun; 15(3):347-371. PubMed ID: 33400146
[TBL] [Abstract] [Full Text] [Related]
14. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.
Ueno H; Yoshida K; Shiozawa Y; Nannya Y; Iijima-Yamashita Y; Kiyokawa N; Shiraishi Y; Chiba K; Tanaka H; Isobe T; Seki M; Kimura S; Makishima H; Nakagawa MM; Kakiuchi N; Kataoka K; Yoshizato T; Nishijima D; Deguchi T; Ohki K; Sato A; Takahashi H; Hashii Y; Tokimasa S; Hara J; Kosaka Y; Kato K; Inukai T; Takita J; Imamura T; Miyano S; Manabe A; Horibe K; Ogawa S; Sanada M
Blood Adv; 2020 Oct; 4(20):5165-5173. PubMed ID: 33095873
[TBL] [Abstract] [Full Text] [Related]
15. dux4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.
Novakova M; Zaliova M; Fiser K; Vakrmanova B; Slamova L; Musilova A; Brüggemann M; Ritgen M; Fronkova E; Kalina T; Stary J; Winkowska L; Svec P; Kolenova A; Stuchly J; Zuna J; Trka J; Hrusak O; Mejstrikova E
Haematologica; 2021 Aug; 106(8):2066-2075. PubMed ID: 32646889
[TBL] [Abstract] [Full Text] [Related]
16. How advanced are we in targeting novel subtypes of ALL?
Mullighan CG
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101095. PubMed ID: 31779973
[TBL] [Abstract] [Full Text] [Related]
17. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.
Zaliova M; Stuchly J; Winkowska L; Musilova A; Fiser K; Slamova M; Starkova J; Vaskova M; Hrusak O; Sramkova L; Stary J; Zuna J; Trka J
Haematologica; 2019 Jul; 104(7):1396-1406. PubMed ID: 30630978
[TBL] [Abstract] [Full Text] [Related]
18. [Strategy for treatment of acute lymphoblastic leukemia].
Kobayashi Y
Rinsho Ketsueki; 2018; 59(10):2019-2027. PubMed ID: 30305504
[TBL] [Abstract] [Full Text] [Related]
19. [Adult acute lymphoblastic leukemia: update on pathophysiology and management].
Hayakawa F
Rinsho Ketsueki; 2018; 59(5):497-503. PubMed ID: 29877239
[TBL] [Abstract] [Full Text] [Related]
20. Structural basis of dux4/IGH-driven transactivation.
Dong X; Zhang W; Wu H; Huang J; Zhang M; Wang P; Zhang H; Chen Z; Chen SJ; Meng G
Leukemia; 2018 Jun; 32(6):1466-1476. PubMed ID: 29572508
[TBL] [Abstract] [Full Text] [Related]
[Next]
